论文部分内容阅读
目的比较两种胰岛素制剂(国产重组甘精胰岛素与NPH胰岛素)联合口服二甲双胍片分别治疗2型糖尿病的有效性和安全性。方法在伊犁州友谊医院2010至2012年门诊及住院患者中抽取90例2型糖尿病患者,随机分为两组,分别在口服二甲双胍(格华止)片的基础上加用国产重组甘精胰岛素(长秀霖)和NPH胰岛素(诺和灵N),治疗观察12周,监测空腹血糖(FPG)和糖化血红蛋白(HbAlc)变化。结果重组甘精胰岛素组患者的FPG和HbAlc水平较低,且重组甘精胰岛素组患者症状性低血糖的发生率低。结论口服降糖药基础上,加用重组甘精胰岛素比NPH更适合作为2型糖尿病患者的基础胰岛素治疗。
Objective To compare the efficacy and safety of two insulin preparations (domestic recombinant insulin glargine and NPH insulin) combined with metformin tablets in the treatment of type 2 diabetes mellitus. Methods Totally 90 patients with type 2 diabetes were selected from outpatients and inpatients in Friendship Hospital of Yili Prefecture from 2010 to 2012 and were randomly divided into two groups. The patients were treated with oral metformin (Gehua Zhide) tablets plus domestic recombinant insulin glargine Chang-Lin Lin) and NPH insulin (norepinephrine N) for 12 weeks. The changes of fasting blood glucose (FPG) and glycosylated hemoglobin (HbAlc) were monitored. Results The levels of FPG and HbAlc in patients with recombinant glargine were lower, and the incidence of symptomatic hypoglycemia in patients with recombinant glargine was lower. Conclusions Oral hypoglycemic agents, based on the use of recombinant insulin glargine NPH more suitable than the type 2 diabetes in patients with basal insulin therapy.